CLDN4 and neoplasm: To examine the tumor-targeting ability of C-LPs in vivo, we intravenously injected Cy5.5-labeled D@LPs or D@C-LPs into athymic nude mice bearing CLDN4-positive KPC960 tumors and monitored the in vivo biodistribution of liposomes over time (Fig. 4A).